Diabetic Retinopathy Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Diabetic Retinopathy Market Overview

Diabetic retinopathy is a major complication associated with diabetes and can progressively affect retinal blood vessels, leading to visual impairment. Increasing diabetes prevalence, growing awareness of eye health, and improved screening are supporting greater attention toward timely detection and treatment. The market is expanding with the adoption of anti-vascular endothelial growth factor therapies, steroid implants, laser procedures, and vitrectomy. Rising demand for minimally invasive treatments, advances in ophthalmic technologies, and improved access to specialized eye care are strengthening market development. The market is poised to reach USD 15.51 Billion by 2035.

Diabetic Retinopathy Market Growth Analysis and Key Influencers

Diabetic Retinopathy Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Diabetic Retinopathy Market Growth Drivers

Innovative Early-Stage Therapies to Strengthen Market Value

The growing emphasis on early intervention in diabetic retinopathy is supporting the development of therapies that address retinal inflammation before irreversible vision loss occurs. For instance, in November 2023, researchers at Washington University in St. Louis demonstrated in a diabetic mouse model that eye injections of CD200Fc reduced microglial activation, retinal inflammation, and visual dysfunction. The approach could enable treatment during earlier disease stages rather than relying primarily on interventions for advanced disease. Such advances in preventive and disease-modifying treatment approaches are expected to expand therapeutic options and support market growth.

Diabetic Retinopathy Market Restraints

High Treatment Costs and Invasive Procedures Limit Market Expansion

The market faces limitations from the invasive nature, cost, and treatment burden associated with established therapeutic approaches. Laser procedures and intravitreal injections can require repeated clinical interventions and may be associated with adverse effects, creating challenges for patients and healthcare providers. These factors can reduce treatment accessibility and patient acceptance, particularly where healthcare resources are limited. The continued dependence on intensive treatment regimens may therefore constrain broader adoption and moderate market expansion.

Diabetic Retinopathy Market Opportunities

Non-Invasive Therapeutic Development Creates New Market Potential

The development of non-invasive and lower-cost treatments represents a significant avenue for future market expansion, particularly for patients requiring early-stage intervention. For instance, in May 2023, D-Sight received a EURO 1 million investment from Clave Capital to advance clinical validation of its therapeutic approach for early-stage diabetic retinopathy. The company highlighted the need for alternatives to invasive laser procedures and intravitreal injections. Continued investment in innovative, safer, and more accessible therapies could address unmet treatment needs and expand future market opportunities.

Diabetic Retinopathy Market Trends

Some of the notable trends in the market are long-acting therapies, continuous drug delivery, and minimally invasive treatment approaches.

Continuous Drug Delivery Is Likely to Enhance Market Growth

The increasing adoption of long-acting and continuous drug delivery approaches is emerging as a significant trend in diabetic retinopathy treatment. For instance, in May 2025, the U.S. Food and Drug Administration approved Roche’s Susvimo for diabetic retinopathy, providing continuous ranibizumab delivery through a refillable ocular implant with refills every nine months. This approach can reduce the frequency of conventional eye injections while supporting vision maintenance, potentially improving treatment convenience and strengthening market growth.

Diabetic Retinopathy Market Share

Non-Proliferative Diabetic Retinopathy Segment Maintains a Strong Market Position

The market is segmented by indication into proliferative diabetic retinopathy and non-proliferative diabetic retinopathy. Among these, the non-proliferative diabetic retinopathy segment led the market, holding the largest revenue share of 70% in the historical period. Its leading position reflects the substantial treatment needs associated with earlier-stage disease and the growing focus on preventing progression before severe retinal damage develops. This segment is expected to maintain its strong position as early diagnosis and intervention continue to gain importance in diabetic retinopathy management.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Diabetic Retinopathy Market Analysis by Region

The regions covered in the report are the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead the market, supported by a substantial diabetic retinopathy patient population and high demand for advanced ophthalmic treatments. According to the Centers for Disease Control and Prevention (CDC), an estimated 9.6 million people in the United States were living with diabetic retinopathy in 2021, including 1.84 million with vision-threatening disease. The substantial disease burden and advanced healthcare infrastructure are expected to sustain market growth.

Leading Players in the Diabetic Retinopathy Market

Diabetic Retinopathy Market Segmentation

Key Questions Answered in the Diabetic Retinopathy Market Report

• What was the diabetic retinopathy market value in 2025?
• What is the diabetic retinopathy market forecast outlook for 2026-2035?
• What are the major factors aiding the Diabetic Retinopathy market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major diabetic retinopathy market trends?
• Which indication is expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the diabetic retinopathy market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report employs a robust mixed-methods research design integrating primary and secondary sources with rigorous validation.

• Primary Research: In-depth interviews with 30+ ophthalmologists, retina specialists, Diabetic Retinopathy procurement managers, and payer representatives across the US, EU5, and Japan—including KOLs affiliated with the American Academy of Ophthalmology (AAO), American Society of Retina Specialists (ASRS), and European Society of Retina Specialists (EURETINA).
• Secondary Research: Peer-reviewed publications from ophthalmology and diabetes journals; regulatory filings from the FDA, EMA, and PMDA; clinical trial data from ClinicalTrials.gov; and epidemiological data from WHO, CDC, NIH, National Eye Institute (NEI), and the Global Burden of Disease study.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops and cross-verification with company annual reports, investor presentations, and press releases.